Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31364605 | 0.83 | ALDH1A1 (0.31) | — | |
| SCHEMBL31364603 | 0.83 | ALDH1A1 (0.31) | — | |
| SCHEMBL2893056 | 0.80 | HRH4 (0.38) | — | |
| Hydrochloric Acid SCHEMBL1308667 | 0.79 | HRH4 (0.37) | — | |
| SCHEMBL13622107 | 0.79 | HRH4 (0.39) | — | |
| SCHEMBL2897271 | 0.79 | HRH4 (0.39) | — | |
| SCHEMBL17654953 | 0.78 | EPHX2 (0.33) | — | |
| SCHEMBL1230783 | 0.77 | — | — | |
| SCHEMBL7555020 | 0.77 | — | — | |
| SCHEMBL7327308 | 0.77 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9359358-B2 | Cyclohexyl azetidine derivatives as JAK inhibitors | INCYTE HOLDINGS CORPORATION (US) | 2016-06-07 | — | — | US | disclosed |
| US-20130045963-A1 | Cyclohexyl Azetidine Derivatives as JAK Inhibitors | INCYTE CORPORATION (US) | 2013-02-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130045963-A1 | Cyclohexyl Azetidine Derivatives as JAK Inhibitors | JAK1, JAK2, JAK3 | IDO1 188/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.